Phase I and translational study of capecitabine, cisplatin, and irinotecan in patients with solid tumors.

被引：0
|
作者：
Verschraegen, CF [1 ]
Lee, FC [1 ]
Rabinowitz, I [1 ]
Mangalik, A [1 ]
Jennings, C [1 ]
Maestas, A [1 ]
Shen, Z [1 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2114
引用
收藏
页码：155S / 155S
页数：1
相关论文
共 50 条
  • [21] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany, Holly Jane
    Dome, Jeffrey
    Hinds, Pamela S.
    Bagatell, Rochelle
    Shusterman, Suzanne
    Widemann, Brigitte C.
    Stern, Emily
    London, Wendy B.
    Kim, AeRang
    Fox, Elizabeth
    Rodriguez-Galindo, Carlos
    Minturn, Jane E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Phase I study of irinotecan in pediatric patients with malignant solid tumors
    Mugishima, H
    Matsunaga, T
    Yagi, K
    Asami, K
    Mimaya, J
    Suita, S
    Kishimoto, T
    Sawada, T
    Tsuchida, Y
    Kaneko, M
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (02) : 94 - 100
  • [23] Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors
    Wilmink, J.
    Deenen, M. J.
    Klumpen, H.
    Sparidans, R.
    Beijnen, J.
    Schellens, J. H.
    Richel, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
    Federico, Sara Michele
    Stewart, Elizabeth
    Coleman, Jamie L.
    Bishop, Michael William
    Santana, Victor M.
    Lam, Catherine
    Hawkins, Dana
    Wu, Jianrong
    Mao, Shenghua
    Goshorn, David Ross
    Papp, Alberto S.
    Dyer, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors
    de Jonge, MJA
    Sparreboom, A
    Planting, AST
    van der Burg, MEL
    de Boer-Dennert, MM
    ter Steeg, J
    Jacques, C
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 187 - 194
  • [26] Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors
    Saltz, LB
    Spriggs, D
    Schaaf, LJ
    Schwartz, GK
    Ilson, D
    Kemeny, N
    Kanowitz, J
    Steger, C
    Eng, M
    Albanese, P
    Semple, D
    Hanover, CK
    Elfring, GL
    Miller, LL
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3858 - 3865
  • [27] A phase I trial of a bi-weekly combination of capecitabine/irinotecan (XELIRI) then capecitabine/irinotecan/oxaliplatin (XELIRINOX) in solid tumors
    Assenat, E.
    Kramar, A.
    Poujol, S.
    Gestin-Boyer, C.
    Senesse, P.
    Samalin, E.
    Portales, F.
    Thezenas, S.
    Bleuse, J.
    Ychou, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors.
    Alsamarai, S.
    Ravage-Mass, L.
    Kaley, K.
    Dutschman, G.
    Zhang, W.
    Jiang, Z.
    Liu, S.
    Cheng, Y. C.
    Chu, E.
    Saif, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A phase I study of the combination of gemcitabine (G), vinorelbine (V) and cisplatin (P) in patients (pts) with solid tumors.
    Schrijvers, D
    Dyck, J
    Van den Brande, J
    Wilmes, P
    Korst, A
    Lardon, F
    Vermorken, J
    ANNALS OF ONCOLOGY, 2000, 11 : 140 - 140
  • [30] Phase I study of SU5416 in combination with CPT-11 and cisplatin in patients with solid tumors.
    Kraut, EH
    Bender, J
    Clinton, S
    Jensen, R
    Balcerzak, S
    Chan, K
    Mueller, C
    Vaswani, K
    Mantil, J
    Christian, B
    Grever, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3661S - 3661S
12345